Top 10 US Synthetic Biology Companies

Mammoth Biosciences has raised $150M+ and is co-founded by CRISPR Nobel laureate Jennifer Doudna to develop ultra-sensitive CRISPR-based diagnostics and next-generation gene editing tools. Its DETECTR platform detects infectious disease biomarkers in under 30 minutes without PCR equipment, targeting 50+ pathogens including SARS-CoV-2, HPV, and monkeypox. The 2025 CE-IVD marking in Europe for its first CRISPR diagnostic kit made Mammoth the first to commercialize regulatory-approved CRISPR diagnostics.

Caribou Biosciences leads with its off-the-shelf CRISPR CAR-T therapies, slashing cancer patient wait times from 4-6 weeks to just 48 hours. The company's chRDNA guide technology achieves 5x fewer off-target edits than standard CRISPR-Cas9, a precision advantage validated in clinical-grade cell manufacturing. Phase 2 data for CB-010 in relapsed B-cell lymphoma reported a 60% complete response rate, outperforming standard-of-care chemotherapy benchmarks and surpassing the 50% rate typical of autologous CAR-T therapies. With $225M raised, Caribou is positioned to rival Inscripta in editing fidelity while targeting a broader oncology market.

Inscripta's digital genome engineering platform, Onyx, performs 10,000+ simultaneous CRISPR edits per day, reducing experiment costs from $10M+ to under $500K per run—a 95% cost reduction compared to traditional methods. This massively parallel capability accelerates metabolic engineering for biofuels and therapeutic proteins, as demonstrated by its 2025 partnership with Novozymes, which embeds Inscripta's technology in the world's largest industrial enzyme pipeline targeting $1B in new sales by 2027.

Modern Meadow produces biofabricated leather from yeast-fermented collagen, eliminating animal slaughter and petrochemical processing while matching traditional leather's texture and durability. Its Zoa material has secured 15+ luxury fashion brand partnerships in 2025, and a scale-up agreement with a NASDAQ-listed chemical company ensures 500-tonne annual production capacity—enabling commercial retail availability for the first time.

Pivot Bio replaces synthetic nitrogen fertiliser with engineered microbes that fix nitrogen directly on crop roots, reducing emissions from the 120M-tonne annual fertiliser market. Its PROVEN 40 product, applied to 6M+ acres in 2024, delivers nitrogen equivalent to 40 lbs/acre of synthetic fertiliser while cutting nitrous oxide emissions by 10% per field. The 2025 USDA organic certification opened the $15B+ organic farming market, doubling Pivot's addressable opportunity.

Mycoworks leads the mycelium leather revolution with its patented Fine Mycelium material, grown in just 10 days yet rivaling premium calfskin in tensile strength and luxury feel. Backed by $125M in funding, its Reishi material has been adopted by Hermès, Stella McCartney, and GM’s Cadillac division, proving viability across luxury fashion and automotive interiors. The 2025 opening of a 70,000-square-foot South Carolina facility signals a leap to industrial scale, targeting 5 million square meters of annual production by 2027.

Zymergen’s legacy endures as the pioneer of machine-learning-driven strain engineering, now consolidated under Ginkgo Bioworks following a $300M acquisition in 2022 that merged the two largest AI-biology platforms in the US. Its bio-based polyimide films target a $2B+ specialty materials market for foldable displays and AR/VR optics, with first commercial samples shipped to three consumer electronics OEMs in 2025. While its commercial output remains nascent compared to Mycoworks’ 5M square meter production target, Zymergen’s IP portfolio offers a 40% reduction in film thickness versus traditional petroleum-based polyimides, unlocking new form factors for flexible electronics and positioning it as a key supplier in the rapidly growing display market.